DM4-SPDP |
Catalog No.GC38460 |
DM4-SPDP est un conjugué médicament-lieur composé d'un puissant agent antitubuline DM4 et d'un lieur SMCC pour fabriquer un conjugué anticorps-médicament. Le SPDP est un agent de réticulation À chaÎne courte pour la conjugaison amine-sulfhydryle via des groupes réactifs NHS-ester et pyridyldithiol qui forment des liaisons disulfure clivables (réductibles) avec des sulfhydryles de cystéine.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2245698-48-8
Sample solution is provided at 25 µL, 10mM.
DM4-SPDP is a drug-linker conjugate composed of a potent antitubulin agent DM4 and a linker SMCC to make antibody drug conjugate[1]. SPDP is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls[2][3].
[1]. Tang R, et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer. 2009 Jun 23;9:199. [2]. Lobedanz S et al. A periplasmic coiled-coil interface underlying TolC recruitment and the assembly of bacterial drug effluxpumps. Proc Natl Acad Sci U S A, 2007 Mar 13, 104(11):4612-7. [3]. Karumuthil-Melethil S et al. Dendritic cell-directed CTLA-4 engagement during pancreatic beta cell antigen presentation delays type 1diabetes. J Immunol 2010 Jun 15, 184(12):6695-708.
Average Rating: 5
(Based on Reviews and 40 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *